20: Curing Cancer with Dr. Mike Olin and Dr. Chris Moertel

In this powerful episode, tumor immunologist Dr. Mike Olin  and pediatric neuro-oncologist Dr. Chris Moertel share how a University of Minnesota discovery, centered on the immune-silencing molecule CD200, sparked a revolutionary clinical trial for one of the deadliest childhood brain cancers.They reveal what it took to get the drug into children, the upcoming Phase 2 trial, and exactly why donor support is the only thing that moves this work forward.In this episode, you’ll learn:The discovery that changed everything: Blocking CD200 so the immune system can finally recognize the tumor.From idea to children: Adult testing ➜ FDA approval ➜ pediatric Phase 1 trial now underway.The next critical step: A multi-site Phase 2 trial led by PI Dr. Anne Bendel, designed to prove efficacy and unlock fast-track access for kids.A smarter, more affordable approach: Focused ultrasound that replaces costly tumor-lysate vaccines and boosts survival in early models.Why funding is urgent: Drug manufacturing, MRI imaging, lab testing, regulatory oversight, and even travel and lodging for families—all dependent on donations.The broader impact: This discovery may also help patients with breast-to-brain metastases and other CD200-positive tumors.Why your donation matters:Every dollar directly accelerates:More kids enrolled in trialsMore drug manufactured and deliveredMore MRIs, labs, and safety testing completedMore families able to travel for treatmentFaster progress toward FDA fast-track approvalEvery contribution moves a child closer to treatment. Support Sally’s mission to raise $1 million for medical research and help bring life-saving treatment to children who need it now.Donate at unstoppablestoriesthatmove.com